Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371244 | 0.90 | ESR1 (0.41) | LMNABCAT2NPC1RAB9AALDH1A1 | |
| SCHEMBL4251422 | 0.85 | CYP19A1 (0.51) | L3MBTL1ATMCYP19A1LMNAALDH1A1 | |
| SCHEMBL27833901 | 0.82 | CYP19A1 (0.49) | L3MBTL1ATMCYP19A1LMNAKDM4E | |
| SCHEMBL6310916 | 0.80 | RAB9A (0.45) | CYP19A1LMNAKDM4ENPC1RAB9A | |
| SCHEMBL10802776 | 0.80 | POLB (0.47) | L3MBTL1ATMCYP19A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9794842 | 0.80 | ALDH1A1 (0.50) | L3MBTL1ATMCYP19A1NPC1RAB9A | |
| SCHEMBL3071656 | 0.80 | ATM (0.44) | L3MBTL1ATMCYP19A1ALDH1A1ELANE | |
| SCHEMBL9048057 | 0.80 | SCN4A (0.50) | L3MBTL1ATMCYP19A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6862384 | 0.79 | KCNA5 (0.51) | L3MBTL1LMNABCAT2KDM4ENPC1 | |
| SCHEMBL6910158 | 0.79 | KCNA5 (0.51) | L3MBTL1LMNABCAT2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070690-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3466922-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | Chubu University Educational Foundation (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-RE39333-E1 | Process for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives | KANEKA CORPORATION (JP) | 2006-10-10 | — | — | US | disclosed |
| EP-1104750-B1 | PROCESSES FOR THE PREPARATION OF 5-HYDROXY-3-OXOPENTANOIC ACID DERIVATIVES | KANEKA CORP (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6340767-B1 | REACTION OF LITHIUM AMIDE WITH ACETIC ACID ESTER AND HYDROXY PROPIONIC ACID | KANEKA CORPORATION (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1104750-A1 | PROCESSES FOR THE PREPARATION OF 5-HYDROXY-3-OXOPENTANOIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070690-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | EBP, NR1H3, APEH | L3MBTL1 4155/4885ATM 2650/4885CYP19A1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.